Jodie is CEO of Q32 Bio and was previously a venture partner and CEO of Cadent Therapeutics until its sale to Novartis in 2020. Previously she served as interim CEO at Keryx Biopharmaceuticals (managed Akebia merger), COO at Syntimmune (acquired by Alexion), and CEO of Tokai Pharmaceuticals (led 2014 IPO). Before her tenure in executive leadership, she held positions in clinical and medical affairs at companies including Dyax, Curis, and Diacrin. Jodie received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College. Jodie has been awarded the Boston Business Journal’s “Power 50” and “Women to Watch” awards and WEST’s “Making a Difference” award.